AI assistant
ARIX BIOSCIENCE PLC Net Asset Value 2023
4968_rns_2023-04-17_640b534b-085b-4419-8668-f23b3b12300e.html
Net Asset Value
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
Arix Bioscience PLC (ARIX)
Unaudited NAV for March 2023
17-Apr-2023 / 07:00 GMT/BST
Arix Bioscience plc
Unaudited NAV for March 2023
LONDON, 17 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 March 2023 as follows:
| Date | NAV Breakdown | Total NAV | NAV per share | |||
| Listed Portfolio | Unlisted Portfolio | Cash | Other Interests | |||
| 31 March 2023 (unaudited) |
£42.9m | £66.6m | £108.7m | £3.1m | £221.3m | £1.71 |
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
| ISIN: | GB00BD045071 |
| Category Code: | MSCL |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 237106 |
| EQS News ID: | 1608427 |
| End of Announcement | EQS News Service |